Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7380MR)

This product GTTS-WQ7380MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7380MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7401MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ7816MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ8031MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ12129MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ815MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ2539MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ10214MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ12426MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NI-0501
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW